НАПРАВЛЕНИЕ НА РАСШИРЕННОЕ ПРИМЕНЕНИЕ


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Приводятся новые данные об успешном применении лефлюномида в ревматологии и других областях медицины. Анализируются сравнительная эффективность лефлюномида и метотрексата и комбинированного их применения при ревматоидном артрите, а также противовирусная активность лефлюномида.

Полный текст

Доступ закрыт

Об авторах

С. Носков

Ярославская государственная медицинская академия

Email: noskov03@gmail.com
доктор медицинских наук, профессор

Т. Носкова

Ярославская государственная медицинская академия

Т. Бахтиарова

Ярославская государственная медицинская академия

Л. Луцкова

Ярославская государственная медицинская академия

Список литературы

  1. Smolen J., Landewé R., Breedveld F. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs // Ann. Rheum. Dis. - 2010; 69 (6): 964-75.
  2. Soubrier M., Puéchal X., Sibilia J. et al. Evaluation of two strategies (initial methotrexate monotherapyvs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial // Rheumatol. (Oxford). - 2009; 48 (11): 1429-34.
  3. Gaujoux-Viala C., Smolen J., Landewé R. et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis // Ann. Rheum. Dis. - 2010; 69 (6): 1004-9.
  4. Jaimes-Hernández J., Meléndez-Mercado C., Mendoza-Fuentes A. Efficacy of leflunomide 100 mg weekly compared to low dose methotrexate in patients with active rheumatoid arthritis. Doubleblind, randomizedclinicaltrial // Reumatol. Clin. - 2012.
  5. Golicki D., Newada M., Lis J. et al. Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials // Pol. Arch. Med. Wewn. - 2012; 122 (1-2): 22-32.
  6. Sakellariou G., Sayegh F., Kapetanos G., Berberidis C. Efficacy of leflunomide addition in relation to prognostic factors for patients with active early rheumatoid arthritis failing to methotrexate in daily practice // Clin. Rheumatol. - 2012; 31 (1): 163-7.
  7. Alves J., Fialho S., Morato E. et al. Liver toxicity is rare in rheumatoid arthritis patients using combination therapy with leflunomide and methotrexate // Rev. Bras. Reumatol. - 2011; 51 (2): 141-4.
  8. De Stefano R., Frati E., Nargi F. et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha // Clin. Rheumatol. - 2010; 29 (5): 517-24.
  9. Benucci M., Saviola G., Baiardi P. et al. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis // Int. J. Immunopathol. Pharmacol. - 2011; 24 (1): 269-74.
  10. Chatzidionysiou K., Lie E., Nasonov E. et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration // Ann. Rheumatol. Dis. - 2012; 71 (3): 374-7.
  11. Yoo H., Yu H., Jun J. et al. Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide // Mod. Rheumatol. - 2012.
  12. Wiese M., Schnabl M., O'Doherty C. et al. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis // Arthritis. Res. Ther. - 2012; 14 (4): R163.
  13. Behrens F., Koehm M., Burkhardt H. Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses // Curr. Opin. Rheumatol. - 2011; 23 (3): 282-7.
  14. Artifoni M., Puйchal X. How to treat refractory arthritis in lupus? // Joint. Bone Spine. - 2012; 79 (4): 347-50.
  15. Bikker A., van Woerkom J., Kruize A. et al. Clinical efficacy of leflunomide in primary Sjogren's syndrome is associated with regulation of T-cell activity and upregulation of IL-7 receptor α expression // Ann. Rheum. Dis. - 2012.
  16. de Souza A., da Silva M., Machado L. et al. Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study // Scand. J. Rheumatol. - 2012; 41 (3): 227-30.
  17. Ash Z., Gaujoux-Viala C., Gossec L. et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and metaanalysis informing the EULAR recommendations for the management of psoriatic arthritis // Ann. Rheum. Dis. - 2012; 71 (3): 319-26.
  18. Boyd A. Leflunomide in dermatology // J. Am. Acad. Dermatol. - 2012; 66 (4): 673-9.
  19. Awad S. Leflunomide is a possible deactivator for vitiligo, a pilot study // J. Eur. Acad. Dermatol. Venereol. - 2011. doi: 10.1111/j.1468-3083.2011.04311.x.
  20. Sehgal V., Verma P. Leflunomide: dermatologic perspective // J. Dermatol. Treat. - 2011; Epub. ahead of print.
  21. Claussen M., Korn T. Immune mechanisms of new therapeutic strategies in MS: teriflunomide // Clin. Immunol. - 2012; 142 (1): 49-56.
  22. Sahoo D., Bandyopadhyay D., Xu M. et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonarysarcoidosis // Eur. Respir. J. - 2011; 38 (5): 1145-50.
  23. O'Donnell E., Kopparapu P., Koch D. et al. PLoS One. - 2012; 7 (7): e40926.
  24. Foeldvari I., Wierk A. Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice // J. Rheumatol. - 2010; 37 (8): 1763-7.
  25. Henao-Martanez A., Weinberg A., Waldman W. et al. Successful treatment of acyclovir-resistant herpes simplex virus type 2 proctitis with leflunomide in an HIV-infected man // J. Clin. Virol. - 2012; 54 (3): 276-8.
  26. Dunn M., Knight D., Waldman W. Inhibition of respiratory syncytial virus in vitro and in vivo by the immunosuppressive agent leflunomide // Antivir. Ther. -2011; 16 (3): 309-17.
  27. Chacko B., John G. Leflunomide for cytomegalovirus: bench to bedside // Transpl. Infect. Dis. - 2012; 14 (2): 111-20.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ИД "Русский врач", 2012